We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

46 hedge funds and large institutions have $8.66M invested in LogicBio Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% less funds holding

Funds holding: 57 → 46 (-11)

57% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 14

71% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 14

77% less capital invested

Capital invested by funds: $37M → $8.66M (-$28.3M)

Holders
46
Holders Change
-11
Holders Change %
-19.3%
% of All Funds
0.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
14
Closed
14
Calls
$14K
Puts
–
Net Calls
+$14K
Net Calls Change
+$41K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$504K
2
VF
Virtu Financial
New York
+$59.4K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$55.2K
4
Bank Julius Baer & Co
Bank Julius Baer & Co
Switzerland
+$21.3K
5
FT
Fiduciary Trust
Massachusetts
+$11K

Top Sellers

Rank Fund Capital Flow
1
SC
Samlyn Capital
New York
-$3.49M
2
Franklin Resources
Franklin Resources
California
-$752K
3
PIM
Platinum Investment Management
Australia
-$740K
4
EP
Eversept Partners
New York
-$672K
5
PVI
Pura Vida Investments
New York
-$532K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$5.76M – – –
Franklin Resources
2
Franklin Resources
California
$621K -$752K -685,119 -43%
Goldman Sachs
3
Goldman Sachs
New York
$346K -$313 -285 -0.1%
Renaissance Technologies
4
Renaissance Technologies
New York
$312K +$504K +459,199 New
BBA
5
Baker Bros. Advisors
New York
$307K – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$218K -$444K -404,761 -56%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$216K +$1.43K +1,300 +0.4%
HCA
8
Harbor Capital Advisors
Illinois
$154K -$61.3K -55,847 -20%
BlackRock
9
BlackRock
New York
$146K -$2.73K -2,493 -1%
SCM
10
Sio Capital Management
New York
$124K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$94K – – –
BCM
12
Bridgeway Capital Management
Texas
$54K -$47.2K -43,000 -35%
VF
13
Virtu Financial
New York
$49K +$59.4K +54,145 +312%
Millennium Management
14
Millennium Management
New York
$34K -$93K -84,742 -63%
FT
15
Fiduciary Trust
Massachusetts
$33K +$11K +10,000 +26%
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$32K +$55.2K +50,339 New
State Street
17
State Street
Massachusetts
$23K – – –
Northern Trust
18
Northern Trust
Illinois
$20K – – –
TYCC
19
Texas Yale Capital Corp
Florida
$14K – – –
Bank Julius Baer & Co
20
Bank Julius Baer & Co
Switzerland
$13K +$21.3K +19,450 New
EWM
21
Endurance Wealth Management
Rhode Island
$12K – – –
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$10K -$11.1K -10,159 -41%
SMH
23
Sanders Morris Harris
Texas
$10K – – –
HSBC Holdings
24
HSBC Holdings
United Kingdom
$8K -$4.3K -3,922 -26%
Morgan Stanley
25
Morgan Stanley
New York
$8K -$1.95K -1,774 -13%
1
2 3

LOGC Hedge Fund Activity: Q1 2022 in Review

46 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q1 2022, worth a combined $8.66M — down 77% from $37M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of LOGC and 4 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $504K. The largest seller was Samlyn Capital, exiting entirely with an estimated $3.49M sold.

  • 46 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q1 2022, down from 57 in Q4 2021.
  • Funds reported $8.66M of LogicBio Therapeutics, Inc. Common Stock stock for Q1 2022, down 77% quarter-over-quarter.
  • 4 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q1 2022 and 14 closed out, a net change of -10 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $504K added.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q1 2022 was Samlyn Capital, an estimated $3.49M sold.

Based on aggregated 13F filings for Q1 2022.